Sirnaomics, Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, today announced a corporate technology spinoff establishing an independent biopharmaceutical company, RNAimmune, Inc. This new entity is focusing on and specializing in messenger RNA (mRNA) based therapeutics and vac
| GAITHERSBURG, Md., June 11, 2020 /PRNewswire/ --Sirnaomics Inc., a leading biopharmaceutical company engaged in the discovery and development of RNAi therapeutics, today announced a corporate technology spinoff establishing an independent biopharmaceutical company, RNAimmune, Inc. This new entity is focusing on and specializing in messenger RNA (mRNA) based therapeutics and vaccine development, with exclusively licensed Polypeptide-Lipid Nanoparticle (PLNP) delivery technology and large scale GMP manufacturing knowledge from Sirnaomics, plus a proprietary artificial intelligence Algorithm for Epitope Prediction and Validation (ALEPVA).
As a clinical stage RNAi therapeutics company, Sirnaomics’ proprietary polypeptide-based delivery technology has been validated in various preclinical and clinical settings, for both local and systemic drug administrations, especially the process development know-how for large scale GMP manufacturing of the drug products, with a global exclusive right. Further evaluation and validation of these technologies including PLNP delivery technology with mRNA vaccine and drug product candidates warrant an expansion of the technology into mRNA delivery beyond siRNA drug products, which led to the creation of RNAimmune earlier this year. Sirnaomics is providing RNAimmune with the increased independence and will have the right to retain an equity investment in RNAimmune. “This is a remarkable development for Sirnaomics, further leveraging our robust technology platform and early-stage product opportunities while maintaining our primary focus on our growing RNAi product clinical pipeline,” stated Patrick Lu, PhD, President and Chief Executive Officer, Sirnaomics, Inc. “RNAimmune is developing a new class of potentially transformative medicines to treat and prevent diseases caused by protein dysfunction and pathogen infections. We continue to believe that our PLNP delivery technology offers advantages over other approaches, especially for the large-scale manufacture, long term storage and remote transportation. We are excited about the robust mRNA delivery effort underway and the promise of further leveraging Sirnaomics broad RNA technology.” “The decision to spinoff RNAimmune as an independent company is the logical next step to unlock value, which will facilitate the ability of RNAimmune to fund itself primarily from sources outside Sirnaomics. After evaluating a variety of approaches, we have concluded that spinning off our mRNA-based therapeutics platform as an independent company offers Sirnaomics the best opportunity to accelerate the development of this exciting technology while enabling additional value creation for its stakeholders from the intellectual property and proprietary technology assets that we have accumulated over the years,” said Allan L. Shaw, Chief Financial Officer, Sirnaomics, Inc. RNAimmune expects to emerge as one of the leading groups for vaccine development against COVID-19 with unique mRNA vaccine design and effective mRNA delivery, under the leadership of Dong Shen, MD & PhD, founder, president and CEO of RNAimmune. Dr. Shen has extensive drug development experience in AstraZeneca and Johnson & Johnson, having led projects across multiple therapeutic areas with high unmet medical need. He has held leadership across early and late programs in the areas of infectious disease, oncology and rare disease. Dr. Shen received numerous awards, including Johnson & Johnson’s Leadership Award in 2018 and Innovation Award in 2017. He received his PhD in molecular oncology from Johns Hopkins University School of Medicine and MD from Shanghai Jiao Tong University School of Medicine. About Sirnaomics, Inc. About RNAimmune, Inc. CONTACT: Sirnaomics, Inc. Westwicke, an ICR Company Media:
SOURCE Sirnaomics, Inc. |
View original content to download multimedia:
